David R. Gandara

Also affiliated with University of California, Davis

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

1.9Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 35 papers — median percentile 0. Top paper: “Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer”.

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209

N/A

3.1DataRank · unranked

105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013

N/A

2.3DataRank · unranked

79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973

Top 11%

1.9DataRank

Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.06.017

N/A

0.975DataRank · unranked

662 citations

Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila, Fabrice Barlési +23 more

Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3947

N/A

0.862DataRank · unranked

21 citations

Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner +10 more

Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.05.001

N/A

0.789DataRank · unranked

18 citations

Karen L. Reckamp, Paul Frankel, Jeff Longmate, Karen A. Kelly, David R. Gandara +7 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7

N/A

0.725DataRank · unranked

125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.10.002

N/A

0.659DataRank · unranked

13 citations

Mary W. Redman, James Moon, Francesco Agustoni, Roy S. Herbst, Thomas J. Semrad +6 more

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.05.021

N/A

0.646DataRank · unranked

73 citations

Victoria M. Raymond, Richard B. Lanman, Jacqulyne Robichaux, Junqin He, Monique B. Nilsson +17 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741

N/A

0.606DataRank · unranked

56 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532

N/A

0.552DataRank · unranked

9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.017

N/A

0.505DataRank · unranked

28 citations

Opeyemi A. Jegede, Suzanne E. Dahlberg, Heather A. Wakelee, Steven M. Keller, William Tester +7 more

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811)

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.02.009

N/A

0.494DataRank · unranked

26 citations

Jieling Miao, Mihaela Cristea, Allen Chen, Jacob Sands, Roy H. Decker +13 more

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.11.020

N/A

0.494DataRank · unranked

26 citations

Robyn Du, Nathaniel J. Myall, Whitney E. Lewis, Natalie Uy, Lingzhi Hong +22 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0.373DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9024

N/A

0.360DataRank · unranked

10 citations

Mary W. Redman, Paul Wheatley‐Price, Bryan A. Faller, Liza C. Villaruz, Larry Corum +10 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003

N/A

0.330DataRank · unranked

8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.07.024

N/A

0.326DataRank · unranked

5 citations

Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev +10 more

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0.208DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576

N/A

0.165DataRank · unranked

2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9075

N/A

0.104DataRank · unranked

1 citations

Mary W. Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi +7 more

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

UNC Libraries(2020)10.17615/74ry-7003

N/A

0DataRank · unranked

0 citations

Editta Baldini, Pierre-Jean Souquet, Grace K. Dy, Ariel López-Chávez, Federico Cappuzzo +25 more

Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.03.004

N/A

0DataRank · unranked

4 citations

Rafael Parra‐Medina, Jonathan W. Riess, David R. Gandara, Luis G. Carvajal‐Carmona, Juan Pablo Castañeda-González

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623

Top 100%

0DataRank

Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001

N/A

0DataRank · unranked

32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors

Cancer Chemotherapy and Pharmacology(2021)10.1007/s00280-020-04224-8

N/A

0DataRank · unranked

22 citations

Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski, Everardo Cobos +6 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.10.015

N/A

0DataRank · unranked

11 citations

Mary W. Redman, Karen Kelly, S. Waqar, Francisco Robert, Gauri Kiefer +6 more

Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6543

N/A

0DataRank · unranked

0 citations

Joseph M. Unger, Qian Lü, Katherine Minichiello, Roy S. Herbst, David R. Gandara +14 more

Data from Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma

(2023)10.1158/1940-6207.c.6544974.v1

Top 100%

0DataRank

Top 100%0 citations

Dmitry Grapov, Johannes F. Fahrmann, Brian C. DeFelice, William N. Rom, Harvey I. Pass +8 more

The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9035

N/A

0DataRank · unranked

0 citations

Mary W. Redman, David Kozono, Sam Callis, Hanna Tukachinsky, Khaled Tolba +14 more

Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations

European Journal of Cancer(2024)10.1016/j.ejca.2024.114024

N/A

0DataRank · unranked

26 citations

Markus Joerger, Yung‐Jue Bang, Ron H.J. Mathijssen, Caicun Zhou, Li Zhang +6 more

State of Lung Cancer in Egypt: Moving Towards Improved Guidelines for Prevention, Screening, Treatment, and Clinical Care Programs

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100776

N/A

0DataRank · unranked

6 citations

Ahmed Magdy Rabea, Philip C. Mack, Janakiraman Subramanian, Ehab Khalil, Mai Sherif +27 more

S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100738

N/A

0DataRank · unranked

4 citations

Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan W. Riess, Tawee Tanvetyanon +8 more

Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100706

N/A

0DataRank · unranked

2 citations

Matthew S. Lara, Miguel López de Rodas, Guillaume Luxardi, Samantha Herbert, Michiko Shimoda +9 more

David R. Gandara

Indexed papers

Top data-sharing exemplar

Papers